Drug Metabolism/Pharmacology News

Brii Biosciences, Vir Biotechnology and VBI Vaccines announced the first patient dosed in a phase 2 trial evaluating combination therapy for the treatment of patients with chronic hepatitis B infection, according to a press release.

Combining therapies with different mechanisms of action to treat non-alcoholic fatty liver disease resulted in greater reduction in liver-related measures, according to a presenter at The Liver Meeting Digital Experience.

From 2013 through 2016, an estimated 2.4 million adults in the United States had a current hepatitis C virus infection. A study published in The American Journal of Public Health reported that the infection rate increased more than twofold between 2004 and 2014 as a result of the opioid epidemic.

From 2013 through 2016, an estimated 2.4 million adults in the United States had a current hepatitis C virus infection. A study published in The American Journal of Public Health reported that the infection rate increased more than twofold between 2004 and 2014 as a result of the opioid epidemic.

Increasing physician experience in the management of Nexavar-related adverse events has led to longer treatment duration and improved overall survival rates in patients with hepatocellular carcinoma, according to results from a nearly 10-year retrospective study.

The American Association for the Study of Liver Diseases Foundation has granted $3.42 million in research and career development awards to 29 researchers and clinicians to conduct liver disease research and undergo advanced hepatology training.

Results from a prospective study of patients with biopsy-proven nonalcoholic fatty liver disease showed that daily aspirin use correlated with less severe histologic features of fatty liver and nonalcoholic steatohepatitis and a lower risk for progression to advanced fibrosis.

VIENNA — Use of adenovirus derived from chimpanzees showed increased activity and sustainability of T cell activation in an early study of a vaccine for hepatitis C virus, according to new data presented during the International Liver Congress.

More than half of patients who presented in hospital with acetaminophen-induced acute liver injury or acute liver failure had undetectable levels of acetaminophen, according to a study recently published in Clinical Gastroenterology and Liver Disease.

CAMP4 Therapeutics and Alnylam Pharmaceuticals announced a collaboration designed to identify new medication targets of an undisclosed rare liver disease with significant unmet need, according to a press release.